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Background: It is known that tissue hypoxia has a positive
impact on malignant progression. Our study was aimed to exam-
ine the correlation between hypoxia-regulated proteins (HRP),
disseminated tumor cells (DTC) and clinical outcome in gastric
cancer (GC).
Methods: One hundred and thirty three naı¨ve patients with pri-
mary GC who underwent surgery were included in the study. All
patients have been informed about investigation. Hypoxia within
tissue was evaluated using 31P NMR spectroscopy (PME/Pi),
expression of hypoxia-inducible factor-1a (HIF-1a) and CD34
(microvessel density – MVD) in tissue were assessed using immu-
nohistochemistry, gelatinases (MMP-2 and -9) activity was deter-
mined with zymography. DTC in bone marrow (BM) were
detected using immunocytochemistry. Statistical analyses were
done using NCSS/PASS package (NCSS, UO, USA).
Results: High hypoxia levels (HLs) were found in 29% of pts.,
and low – in 71% of pts. Strong nuclear expressions of HIF-1a
were found in 7%, moderate – in 80%, and weak – in 13% of
pts. Strong MVDs were observed in 54% and moderate – in
46% of pts. It was revealed a close association of HL in tumor
both with expression of HIF-1a in tumor cells (P < 0.01) and
MVD rate (P = 0.02). The HIF-1a expression correlated with histo-
logical grade of tumor (P < 0.05). HL and MVD in tumor corre-
lated with clinical stage (P < 0.05). It was shown that increased
PME/PDE ratio in tumor may be associated with the early devel-
opment of distant metastases. It was also shown that tumor
cells in BM are detected in 40% of patients with M0 stage. It
was observed that tumor in patients with negative BM is charac-
terized both by high MMP-9 activity and low level of hypoxia. At
the same time tumor in patients with positive BM is character-
ized both by high activity of MMP-2 and high level of hypoxia.
High tumor HL positively correlated with decreased overall sur-
vival (P = 0.044). For overall survival, HL and HIF-1a expression
were independently predictive in multivariate analysis for
lymph-node negative patients.
Conclusion: Statistical analysis has indicated that PME/Pi and
PME/PDE ratios as well as HIF-1a expression in tumor tissue
may be used as an independent prognostic factors of clinical out-
come in patients with GC. It is supposed that hypoxic profile of
tumor can be a favourable basis for the appearance of DTC and
formation of distant metastases.
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A. Dimmler, W. Hohenberger. Erlanger, Germany.Introduction: Primary gastric carcinomas more commonlyappear in advanced age; the portion of younger patients with this
(<50 years) is about 7–15%. To discover possible clinical and path-
ologic peculiarities between the two groups, our clinic’s patients
who were under 50 years of age were compared to patients who
were over 50 (n = 481).
Materials and Methods: The study’s time-frame spanned from
01/01/1994 to 12/31/2002. The younger-aged group (median age
44 years) was composed of 73 afflicted patients; the older-aged
group (>50 years) was composed of 408 operated patients (median
age 68 years).
Results: Younger patients reported symptoms preoperatively
more often than older patients (99% vs. 92%, p > 0.05%). The dif-
fuse gastric carcinoma predominated the younger collective of
patients (82% vs. 49%, p = 0.0001). In differentiating the tumor
stages, there were minimal differences between the two groups
(p > 0.05%). Postoperative complications in the sense of insuffi-
cient anastomoses was remarkably higher in older patients (5%)
as compared to younger patients with 1% (p = 0,22559). There
were remarkable differences in survival (5-year survival rate) in
favor of the younger patients even after statistical age corrections
were performed (54.1% vs. 41.1 %; p = 0,0414).
Conclusion: In younger patients, the diffuse type predominates,
which could point to differences in genesis. It is often only ini-
tially found in a late stage (IV) and is always associated with clin-
ical symptoms. The treatment results in younger patients are
more favorable than in the >50 group, not only in the view of
the surgical complications, but also in lethality and 5-year sur-
vival. This is also true in consideration of the different life expec-
tancies and gender differences.
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Background: Currently there are no tests to assist in selecting
the optimal preoperative chemotherapy (PST) regimens for breast
cancer patients. Primary study goals are pathologically confirmed
tumour response and the rate of breast conserving therapy. Sec-
ondary study goals are to find histopathologic and gene profiling
patterns best correlating with tumour remission in a TEC based
neoadjuvant setting as well as to evaluate cytostatic toxicity
and quality of life.
Metohds and Patients: In this neoadjuvant phase II study of
totally 40 eligible patients with histologically confirmed invasive
breast cancer Human Genome Survey Microarray (HGSM) expres-
sion profiling is preformed on jet-biopsy sample basis. The
protocol was elaborated for the treatment of breast cancer
patients suffering from a primary tumour greater than 1.5 cm or
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